Press release: AdvanceCOR GmbH announces completion of recruitment of patients with symptomatic stenosis of the carotid artery suffering from ischemic stroke in a clinical phase II study on Revacept vs. placebo

Munich, December 2018 – AdvanceCOR GmbH announces the recruitment completion of the first phase II study with Revacept®. This phase II study in patients with symptomatic carotid artery stenosis (TIA or stroke, NCT01645306) investigates micro-infarctions in the brain by MRI tomography, micro-embolic signals in brain arteries (determined by ultrasound), clinical results, and bleeding complications. The study is carried out in double-blinded and randomized fashion with two doses of Revacept and a placebo control group. The anticipated patient recruitment of 150 patients has been achieved – so far, no relevant adverse effects have been observed. The safety analysis shows a signal for increased anti-ischemic effects with reduced ischemic strokes and myocardial infarctions compared to similar patient cohorts from previous studies. Due to the blinded study design, the final analysis of efficacy is currently under way.

A second investigator-initiated phase II clinical study in patients with coronary artery disease (NCT 03312855; EudraCT 2015-000686-32) has been initiated by the team of Prof. Adnan Kastrati, German Heart Center, Munich and the team of Prof. Steffen Massberg, Großhadern Clinic of the Ludwig-Maximilian University. Other clinical entities who cooperate within the German Center for Cardiovascular Diseases (DZHK) also contribute. In this randomized, double-blinded placebo controlled study, more than half of the anticipated number of 332 patients have so far been recruited. No increase in bleeding complications and also a signal for reduced ischemic complications (myocardial infarction and stroke) was noted.

About Revacept
Revacept is a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury, acting like a “vascular coating”. Efficacy studies showed that Revacept resulted in significantly reduced thrombus formation at these sites. However, systemic hemostasis is not affected.
In a first in man study, all doses were well tolerated, no drug-related adverse events occurred, bleeding time was not prolonged. The expected inhibitory effect on platelet aggregation was measured in a dose-dependent fashion in the blood of the individuals whereas no bleeding complications nor platelet depletion (thrombopenia) were observed.

About AdvanceCOR GmbH
AdvanceCOR GmbH is a biotechnology company located in Martinsried near Munich, Germany. AdvanceCOR owns several clinical and preclinical projects generated from its own scientific program or from the university groups of the company’s founders.

For more information please contact
AdvanceCOR GmbH
Prof. Dr. Götz Münch
Fraunhoferstr. 9a
D-82152 Martinsried
Tel. ++49 (0)89 2000 204 10
Email: info@advancecor.com
www.advancecor.com